---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-003931"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:33:09.611192+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vera Therapeutics appoints new CMO and CDO; prior CMO departed

## Summary
- Dr. Celia Lin separated as CMO effective Jan 3, 2024; received target 2023 bonus and severance.
- Dr. Robert Brenner appointed CMO effective Jan 3, 2024; brings 25+ yrs nephrology and biotech experience.
- William D. Turner appointed CDO effective immediately; led drug development, NDA/MAA filings at Sierra and Aimmune.
- Both execs to support atacicept Phase 3 trial in IgA nephropathy and pipeline development.

## SEC filing metadata
- accession: 0001193125-24-003931
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000119312524003931/0001193125-24-003931-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000119312524003931/d110151d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-003931
- JSON: https://secwatch.observer/filing/0001193125-24-003931.json
- Plain text: https://secwatch.observer/filing/0001193125-24-003931.txt

## Key facts
- Executive change
  Celia Lin departed as Chief Medical Officer at Vera Therapeutics, Inc..
  - Action: separated
  - Role: Chief Medical Officer
  source text: On January 8, 2024, Vera Therapeutics, Inc. (the "Company") announced that Celia Lin, M.D., the Company’s Chief Medical Officer, had separated from the Company effective January 3, 2024 (the "Separation Date").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831828/000119312524003931/0001193125-24-003931-index.htm
- Executive change
  Robert M. Brenner was appointed as Chief Medical Officer at Vera Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Medical Officer
  source text: The Company appointed Dr. Robert M. Brenner, M.D., to succeed Dr. Lin as the Company’s Chief Medical Officer, effective January 3, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831828/000119312524003931/0001193125-24-003931-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.